Koninklijke Philips N.V. is a health technology company that develops products and solutions for professional healthcare and personal well-being. The company operates in the professional healthcare sector, offering patient monitoring, ultrasound imaging, medical information and diagnostics, and image-guided therapy. It also provides consumer health products, including electric shavers and personal care devices, under the Philips brand. Philips serves healthcare providers, hospitals, and consumers globally. The company partners with healthcare providers, start-ups, universities, and other businesses to drive innovation in health technology. Founded over a century ago, Philips focuses on meaningful innovation to improve patient care and quality of life.

Summarised from the company's own disclosures, fiscal year ended Oct 2026

Industry Medical Devices Homepage philips.co.th
Sector Healthcare IR page philips.com/a-w/about/investor-relations
Tags
patient monitoring, ultrasound imaging, medical diagnostics, image-guided therapy, personal care, electric shavers, health technology, professional healthcare, consumer health, Philips, i9000 Prestige Ultra, SkinIQ Pro
Press page philips.co.th/a-w/about/news

Metrics

Valuation  
Market cap € 23.165B
Market cap (USD) $ 25.408B
P/E 23.13
PEG —
P/BV 1.86
P/S 1.14
P/OCF 17.41
P/FCF 40.48
Dividend yield 0.12%
Turnover / mcap —
Returns  
ROE 7.8%
ROI 4.7%
ROIC 5.7%
Profit margin 5.0%
Growth  
Revenue growing No
Profits growing Yes
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock No
Diluting (TTM) Yes
Debt/Equity 73.1%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 36
Quality score -16.7%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009
Revenue 17.834B 18.021B 18.169B 17.827B 17.156B 19.535B 19.482B 18.121B 17.78B 17.422B 24.244B 21.391B 23.329B 24.788B 22.579B 25.419B 23.189B
Net profit 895M -702M -466M -1.608B 3.319B 1.187B 1.167B 1.09B 1.657B 1.448B 645M 415M 1.166B 221M -1.299B 1.44B 396M
Free cash flow 504M 893M 1.492B -979M 866M — — — — — 325M 497M 551M 1.523B 111M 1.503B 1.021B

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009
Share price 23.03 23.05 21.43 14.89 31.26 46.34 43.89 30.19 32.18 27.38 22.89 21.88 27.92 21.23 14.82 23.78 20.58
Price performance 12m 0.07 0.09 0.56 -0.59 -0.32 0.11 0.39 -0.07 0.24 0.2 -0.12 -0.22 0.39 0.27 -0.32 0.04 —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (EUR) 8.46B — — — — — — — — —
↳ YoY growth +1.9%
↳ 5y CAGR +15.2%
Borrowings, current (EUR) 15.8B — — — — — — — — —
Borrowings, non-current (EUR) 2.6B — — — — — — — — —
Cash and deposits (EUR) 756M — — — — — — — — —
Intangible assets (EUR) 80M — — — — — — — — —
Net debt (borrowings + leases - cash) (EUR) 17.7B — — — — — — — — —
Cash flow detail
Operating cash flow (EUR) 1.9B — — — — — — — — —
Purchases of property, plant and equipment (EUR) -831M — — — — — — — — —
Free cash flow (OCF - PPE - intangibles) (EUR) 1.07B — — — — — — — — —
Income detail
Research and development expense (EUR) 2.02B 1.76B 1.76B 1.88B 1.92B 1.81B 2.1B 1.89B 1.75B 1.7B
↳ 5y CAGR +4.7% -0.5% +0.3% +2.9% -0.1% -2.2% +3.6% +1.4% -1.5% -2.4%
Reported Feb 21, 2017 Feb 20, 2018 Feb 27, 2019 Feb 25, 2020 Feb 23, 2021 Feb 22, 2022 Feb 21, 2023 Feb 20, 2024 Feb 21, 2025 Feb 19, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Prinses Irenestraat 59

This report comprises a copy of the following report:

“Philips' Third Quarter Results 2026”, dated November 3, 2026.

Philips delivers strong order intake growth, comparable sales growth and strong margin expansion in Q3; 2026 outlook reiterated

Amsterdam, November 3, 2026

Q3 2026 Group performance

•Comparable order intake increased by 8%, driven by strong Diagnosis & Treatment

•Group sales of EUR 4.4 billion, reflecting 3% comparable sales growth

•Income from operations of EUR 165 million

•Adjusted EBITA margin increased 70 basis points to 13.0%, with expansion across all business segments

•Operating cash flow of EUR 544 million; free cash flow of EUR 384 million

•Respironics reached agreement in principle with the US Department of Justice

•Philips reiterates its full-year 2026 outlook

Roy Jakobs, CEO of Royal Philips:

“We delivered an excellent 8% comparable order intake, led by broad-based order momentum in Diagnosis & Treatment, and 3% comparable sales growth in the third quarter, led by Personal Health and Connected Care. Our innovations and productivity measures drove continued margin expansion across all business segments.

Nov 03, 2026 | 1 minute read

Financial performance News article

Following the publication of Philips’ Q3 2026 results on November 3, 2026, CEO Roy Jakobs joined Bloomberg to discuss the company’s financial and business performance, highlighting growth of order intake, strong demand for Philips' innovations, margin outperformance and an agreement in principle with the US DOJ.

Roy Jakobs, CEO of Royal Philips, discusses Philips’ Q3 2026 results in an interview with Bloomberg on November 3, 2026.

Media contacts

Kees Verheij--Philips Global External Relations

Kees Verheij

Philips Global External Relations

Philips delivers strong order intake growth, comparable sales growth and strong margin expansion in Q3; 2026 outlook reiterated

Nov 03, 2026 | 4 minute read

Financial performance Press release

Q3 2026 Group performance

  • Comparable order intake increased by 8%, driven by strong Diagnosis & Treatment

  • Group sales of EUR 4.4 billion, reflecting 3% comparable sales growth

  • Income from operations of EUR 165 million

  • Adjusted EBITA margin increased 70 basis points to 13.0%, with expansion across all business segments

  • Operating cash flow of EUR 544 million; free cash flow of EUR 384 million

  • Respironics reached agreement in principle with the US Department of Justice

  • Philips reiterates its full-year 2026 outlook

Roy Jakobs, CEO of Royal Philips:

“We delivered an excellent 8% comparable order intake, led by broad-based order momentum in Diagnosis & Treatment, and 3% comparable sales growth in the third quarter, led by Personal Health and Connected Care. Our innovations and productivity measures drove continued margin expansion across all business segments.

We are executing our plan to accelerate profitable growth, with strong customer demand for our latest AI-enabled innovations, including our new CT platforms Verida and Rembra, our latest ultrasound system Alturion, and our HealthSuite Imaging cloud solution. These innovations demonstrate how our platforms bring together hardware, software, data and AI to create greater value for customers. We look forward to showcasing our next innovations at RSNA later this month.

We continue to make progress in resolving the consequences of the Sleep & Respiratory Care recall. The Respironics agreement in principle with the US Department of Justice marks an important step in this process.

Our year-to-date results, together with our strong order book, give us confidence in delivering our full-year outlook and achieving our medium-term ambitions. As we move forward in collaboration with customers, our hardworking teams around the world are focused on putting quality at the heart of our operations as we deliver better care for more people.”

Robotics and advanced imaging

Group and segment performance

Comparable order intake grew 8%, driven by strong growth in Diagnosis & Treatment. Comparable sales increased by 3%, driven by Personal Health and Connected Care.

Adjusted EBITA margin increased 70 basis points to 13.0%, mainly driven by higher sales, higher gross margin and productivity measures, partly offset by cost inflation. Net cash flows from operating activities increased to EUR 544 million, mainly driven by higher cash earnings and lower working capital outflows. Free cash flow increased to EUR 384 million.

Diagnosis & Treatment comparable sales growth was flat. Growth in Image Guided Therapy was offset by a decline in Precision Diagnosis, mainly due to phasing of Ultrasound sales and lower sales in China as previously communicated at Q2. Adjusted EBITA margin increased 50 basis points to 12.3%, mainly driven by gross margin from innovation and productivity measures, partly offset by cost inflation.

Connected Care comparable sales increased by 5%, driven by growth in all businesses. Adjusted EBITA margin increased 190 basis points to 13.3%, mainly driven by higher sales, higher gross margin, and productivity measures, partly offset by cost inflation.

Personal Health comparable sales increased by 8%. Adjusted EBITA margin increased 60 basis points to 17.7%, mainly driven by higher sales and productivity measures, partly offset by advertising and promotion spend.

Connecting across healthcare settings

Innovation highlights

  • Philips is accelerating innovation in image-guided therapy. In the Netherlands, Philips is investing EUR 50 million in AI, robotics and advanced imaging, alongside over EUR 100 million from the Dutch government and a further EUR 150 million in private financing by Invest-NL and institutional investors, including pension funds. In the US, an ARPA-H award of up to USD 34 million will support AI-enabled robotic stroke care on the Azurion platform.

  • The Philips-coordinated European COMBINE-CT project advanced into clinical validation, launching five clinical studies to evaluate an integrated care pathway enabled by AI-powered CT and Spectral CT imaging solutions.

  • Philips extended its monitoring partnership with one of the largest US health systems through 2034. The national agreement covers equipment and services, expands the use of Philips’ Capsule platform, and supports future technology needs.

  • Ontario Health in Canada selected the Philips Enterprise Imaging Vendor Neutral Archive to modernize province-wide imaging infrastructure and connect patient information across care settings. This Vendor Neutral Archive will support the sharing of more than 20 million imaging studies annually across more than 150 hospitals and 50 imaging clinics, helping enable a holistic patient view and more timely access to care.

  • Philips is supporting major healthcare programs in Latin America, including the modernization of 50 public hospitals in Venezuela, and an expanded partnership with Mexico’s largest public healthcare institution, IMSS. The projects bring advanced imaging, image-guided therapy and monitoring technologies to more patients, expanding access to diagnostic, cardiac, neurological and stroke care.

  • Philips signed a long-term strategic partnership with Asia Medical Group to advance integrated cardiovascular care in China. The partnership will focus on clinical care, training, research and international collaboration, combining Philips’ diagnostic imaging and image-guided therapy capabilities with Asia Medical Group’s cardiovascular expertise.

  • Personal Health launched innovations across oral care, beauty and mother and child care. These include the AI-powered Sonicare DiamondClean 9900 Prestige, the first at-home IPL with real-time guidance Lumea 9900 Pro, and Philips Avent’s first fully wearable Natural Care breast pump, bringing more personalized and premium solutions to consumers.

Productivity

Disciplined cost management and productivity initiatives delivered EUR 170 million in net savings in the quarter and EUR 427 million year-to-date. The company remains on track to deliver EUR 1.5 billion in savings under its 2026-2028 productivity program.

Progress on Respironics-related legal proceedings

Philips Respironics reached an agreement in principle with the US Department of Justice (DOJ) to resolve the previously disclosed criminal and civil investigations related to the Respironics recall. As a result, Philips recorded a provision of EUR 288 million in the third quarter of 2026. The settlement is subject to finalization of the relevant documentation; payment is expected in the first quarter of 2027.

Also in the third quarter, the Enterprise Chamber of the Amsterdam Court of Appeal denied requests from certain investors for an investigation into the affairs of Philips in connection with the Respironics recall.

Outlook

Philips reiterates its full-year 2026 outlook:

  • Comparable sales growth: 3%-4.5%

  • Adjusted EBITA margin: 13.5%-14.0%, including a US tariff refund benefit of approximately 1%

  • Free cash flow: EUR 1.5-1.7 billion, including a net US tariff refund benefit of approximately EUR 200 million

Within the context of an uncertain macro-environment, Philips' 2026 outlook includes currently known tariffs and assumes payment of the US Department of Justice settlement in the first quarter of 2027. The outlook excludes other ongoing Philips Respironics-related proceedings, including the investigation by the US State Attorneys General.

Capital allocation

In the third quarter, Philips issued EUR 650 million fixed rate notes due 2034 (the “Notes”) under its European Medium Term Note program. The Notes are the healthcare industry's first EU Green Bond under the new European Green Bond Standard and were 2.7 times oversubscribed, reflecting strong investor demand. An amount equivalent to the gross proceeds will be used to finance taxonomy-aligned economic activities as referred to in the Philips European Green Bond Factsheet, supporting Philips in delivering on its 2030 Impact Ambitions. See here for more information on Philips' current debt structure.

Philips Q3 2026 results downloads

Visit our results hub to download the latest Report and Presentation, and learn more about our results and sustainability performance.

Results hub

Further information: conference call, video webcast and website

Roy Jakobs, CEO, and Charlotte Hanneman, CFO, will host a conference call for investors and analysts at 10:00 am CET on November 3, 2026, to discuss the results. A live webcast will be available on the Philips Investor Relations webpage and can be accessed here. A replay and related materials, including additional information on the outlook and forward-looking statements, will be available on the Philips Investor Relations webpage.

More information about Roy Jakobs and Charlotte Hanneman

Click here for Roy Jakobs' CV and images Click here for Charlotte Hanneman's CV and images

Media contacts

Michael Fuchs--Philips Global External Relations

Michael Fuchs

Philips Global External Relations

Prompts

Koninklijke Philips N.V. NY Registry Shares (ticker PHG), listed in United States.

Company History

Date Change Detail
Jul 22, 2013 Renamed KONINKLIJKE PHILIPS ELECTRONICS NV → KONINKLIJKE PHILIPS NV

ETFs Holding Koninklijke Philips N.V. NY Registry Shares

ETF Weight in ETF Shares Market value As of
LGHT 4.62% 4,202 $ 114.252K Jun 30, 2026
CVGD 2.20% 116,027 $ 3.052M Jul 31, 2026
BINV 1.89% 341,084 $ 9.274M Jun 30, 2026
BSMC 0.97% 59,390 $ 1.615M Jun 30, 2026
APIE 0.29% 126,246.9969 $ 3.354M Aug 31, 2026
DFIV 0.13% 995,485 $ 29.914M Nov 12, 2026
DFSI 0.10% 40,958 $ 1.231M Nov 12, 2026
DFIC 0.08% 403,230 $ 12.117M Nov 12, 2026
DFAI 0.05% 314,619 $ 9.454M Nov 12, 2026
DFAX 0.04% 168,902 $ 5.076M Nov 12, 2026
AVDE 0.04% 288,917 $ 8.708M Nov 16, 2026
DXIV 0.03% 2,650 $ 79.633K Nov 12, 2026
AVSD 0.03% 3,315 $ 99.914K Nov 16, 2026
VOXP 0.03% 60 $ 1,578.00 Jul 31, 2026